Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.
What is Milestone Pharmaceuticals's quote symbol?
What is the 52 week high and low for Milestone Pharmaceuticals (NASDAQ: MIST)?
How much is Milestone Pharmaceuticals stock worth today?
How much is Milestone Pharmaceuticals's stock price per share?
What is Milestone Pharmaceuticals's Market Cap?